The antimicrobial, antifungal and anti-inflammatory properties of tea tree oil (TTO), the essential oil of Melaleuca alternifolia are well documented. In order to optimize its therapeutic activity, TTO patches were designed. The aim of this work was the formulation of monolayer patches containing TTO. Moreover, the performance of oleic acid (OA) as a skin penetration enhancer in patches was evaluated. Terpinen-4-ol (T4OL), the main component of TTO, was the marker used to evaluate TTO skin permeability. The permeation study was performed through human epidermis by using Franz diffusion cells. Patches were prepared by using methacrylic copolymers, Eudragit E100 (EuE100) or Eudragit NE (EuNE), and a silicone resin, BioPSA7-4602 (Bio-PSA). TTO and OA contents were fixed at 10% w/w and 3% w/w, respectively. The patches were prepared by a casting method and characterised in terms of T4OL content and skin permeability.
Tea tree oil (TTO) is the essential oil steam-distilled from Melaleuca alternifolia, known for its antimicrobial, antifungal and anti-inflammatory properties. The fungicidal and bactericidal actions of the oil seem well established. Data from Hammer's study supported the hypothesis that TTO exerts its antifungal action by altering membrane properties and compromising membrane-associated functions [1] . The anti-inflammatory and anti-oxidative effects remain unclear. Caldefie-Chezet et al. concluded that TTO may be both a direct active mediator of the bactericidal action of the circulating leukocytes and an efficient agent in protecting the organism from an excess of reactive oxygen species, through an antioxidant and radical scavenging activity [2] . TTO is widely recommended for the treatment of acne vulgaris, a disease of the pilosebaceous unit [3] . Topical treatment is usually preferred in mild to moderate acne.
Major components of TTO are terpinen-4-ol (T4OL), terpinene and α-pinene.
Considering the antimicrobial effect, T4OL, α-terpineol and α-pinene were found to be active against Staphylococcus aureus, S. epidermidis and Propionibacterium acnes, whereas 1,8-cineole was inactive against these organisms. The MIC values of the three active components increased in the order α-terpineol < T4OL < α-pinene for the three microorganisms. The MIC values of TTO and T4OL were lower for Propionibacterium acnes, the major bacterium that causes acne vulgaris, than for the two staphylococci [4] . This study demonstrated that T4OL is not the sole active constituent in TTO, while Fletcher et al. suggested that T4OL may contribute significantly to the widely reported antibacterial activity of TTO [5] . Among TTO constituents, the Australian Standard sets compositional limits for T4OL, due to its major activity, and for 1,8-cineole, that is inactive, but has a putative irritant effect.
Recent evidence has demonstrated that exposure to TTO can lead to allergic contact dermatitis in susceptible individuals. These cases are most probably due to the yellow or even sticky green-to brown-colored, viscous liquid residue found in empty bottles. TTO is commercially available as pure, freshly distilled oil in bottles. Unfortunately, oil use leads to the opening the TTO bottle every day, taking a small amount out and then closing it again. The older the oil during the handling, the more extended the patients' reactions [6, 7] . An alternative mode of use able to reduce the TTO oxidation due to light, warmth, moisture and oxygen, that is likely to take place during the daily opening of bottles, could be of interest. The development of a patch able to control TTO percutaneous absorption could optimise the safety and efficacy of the treatment.
A previous study was made of human skin permeability of T4OL, the main component of the essential oil, in combination with some liquid excipients (1:1) widely used in semisolid formulations as solubilizing agents and/or penetration enhancers. Only oleic acid (OA) was shown to be really effective for enhancing the permeability of T4OL, both considering permeation and penetration data [8] . The aim of this present work was the formulation of monodose patches containing TTO. Moreover, the performance of OA as a skin penetration enhancer in patches was evaluated.
The designed patches were monolayer devices made of a flexible backing layer, a self-adhesive controlled release matrix containing TTO and a removable protecting foil. They were prepared by using pressure sensitive adhesives based on Eudragit E100, (EuE100), a poly(aminomethyl methacrylate), Eudragit NE40D (EuNE), a poly(ethyl acrylatemethyl methacrylate) or BioPSA7-4602 (Bio-PSA), a silicone resin; the final composition of the dried matrices are shown in Table 1 . The patches were characterized in terms of drug content and ex-vivo skin permeation. T4OL was the marker used to evaluate the TTO skin permeation. The permeation profile was determined through human epidermis by using Franz diffusion cells. The retained amount of T4OL in the epidermis was also determined, as the target of TTO is mainly the upper layer of the skin. Control patches without OA were used to confirm its enhancement effect. All polymeric systems were suitable for the preparation of TTO patches. The T4OL contents of all the patches were not significantly different ( Table 2 ).
The T4OL skin permeation profiles obtained from patches are reported in Figure 1 . A linear profile was always observed both with and without the permeation enhancer (R 2 : 0.95 -0.99). Only in the case of patch 1A, was a lag time phase of about 1.5 h observed.
The formulations based on BioPSA led to the highest fluxes. The fluxes of the methacrylic patches without OA were about half those obtained by using the silicone matrix.
In the case of patches of the series 1 and 2, the OA addition did not increase the T4OL skin permeability. Only in the case of patches of the series 3 was the enhancement effect of OA significant (p<0.05, Table  2 ) and the flux was in the same order of magnitude of the silicone patches. In a previous study [8] the permeated amount of T4OL obtained by using the pure TTO was 556 μg/cm 2 . The skin permeation of T4OL was significantly enhanced when TTO was used in combination (1:1) with OA. In this case, the permeated amount of T4OL was up-to 10-fold higher (6063 μg/cm 2 ) with respect to those obtained when pure TTO was used. Naik et al. [9] suggested that OA acts by forming separate domains which break up the continuity of the multilamellar structure and may induce highly permeable pathways in this domain.
Probably the solvent flux through the stratum corneum could explain the huge enhancement effect of OA towards T4OL permeation. The lack of the enhancement effect in patches of the series 1 and 2 could probably be due to a different interaction of OA in the matrix that hindered its release and, therefore, prevented its effect on the epidermal layer.
In the case of patches of series 1, it could be supposed that there was an interaction between EuE100, a cationic methacrylic copolymer, and the fatty acid. In the case of patches of series 2, OA could be trapped by the silicone resin through a condensation reaction with a silanol endblocked polydimethylsiloxane produced by the adhesive [DOW CORNING ® BIO-PSA 7-4602 SILICONE ADHESIVE, Product Data Sheets]. The retained amounts of T4OL in the epidermis are reported in Table 2 . The lowest amounts were determined for patches of series 3.
Considering that the main critical issue in the use of TTO is the toxicity related to its absorption, the patches based on the poly(aminomethyl methacrylate) EuE100, which presented the highest retained amount and the lowest permeation of T4OL, seem the most suitable for the local administration of TTO. Furthermore, since these preliminary data seem to indicate that the loading of OA in this matrix slightly increased the retained amount without affecting the flux through the human epidermis, this penetration enhancer could be useful to optimise the efficacy and safety of TTO patches.
Experimental
Materials: Tea Tree Oil (TTO), density=0.8942 g/mL, concentration of terpinen-4-ol 42.7% w/v (ACEF Spa, Italy); (-)-terpinen-4-ol 97% (Acros Organics, USA); internal standard: camphor 96% (Sigma Aldrich, Germany 
Preparation of matrix mixtures:
The mixtures used for the preparation of the patches (Table 1) were made as follows. All mixtures were used after 12 h of rest.
Patch 1A and 1B: PVP was added slowly to isopropanol in order to obtain a 20% w/w solution. EuE100 and PEG400, used as plasticizer, were added in the appropriate amounts and the slurry was kept stirred with a paddle stirrer up to complete solubilization. Then, TTO and, when necessary, OA were added to the organic solution.
Patch 2A and 2B: TTO and, when necessary, OA were added to BioPSA7 and the system was kept stirred with a paddle stirrer until homogeneous dispersion had been obtained.
Patch 3A and 3B: TTO and ATBC, which acted as a plasticizer for EuNE, and OA, if required, were mixed to obtain a homogeneous solution. Then, the methacrylic copolymer was added and the slurry was kept stirred with a paddle stirrer until homogeneous dispersion had been obtained.
Preparation of patches:
The matrix mixture was spread on the backing layer at a constant rate of 1m/min with a thickness set in order to achieve a final thickness of 70 μm. The system was dried at 60°C for 15 min. After that, the matrix was covered with a protective foil and stored at 20°C in aluminum packaging until use. The patches were prepared by using a laboratory coating unit Mathis LTE-S (M) (CH).
Drug content:
A patch sample of 2.54 cm 2 was solubilized with 20 mL methanol in the case of patches of series 1 and 3 and 20 mL ethyl acetate in the case of patches of series 2. The solution was sonicated for 30 min and then filtered through a Durapore® filter, with a pore size of 0.45 mm (Millex® GV, Millipore Corporation, Bedford, MA, USA) and assayed by the CGC/FID method reported below. Each value represents the average of three samples.
Skin membrane preparation:
The human skin used in this transdermal permeation study was obtained from abdominal surgery clippings, with consent of the patient (one single female) and ethical approval according to the Declaration of Helsinki of the World Medical Association. Experiments were performed by using the same donor skin to reduce any variation from using skin from different patients. The fullthickness of skin was prepared within 24 h after removal. Excess fatty and connective tissues were carefully removed and the skin sections were cut into squares. The samples were stored at -20°C for periods not exceeding 12 months [10] . Prior to use, the skin sections were defrozen to room temperature and prepared by the heat separation technique. After immersing the skin in water at 60°C for 1 min, the stratum corneum and epidermis (SCE) were gently separated from the underlying dermis with forceps. The SCE was carefully inspected visually for any defects before mounting it onto the Franz diffusion cells.
Ex vivo skin permeation:
The epidermal skin layer was carefully mounted on the lower half of the Franz cell with the epidermis facing upwards and the stratum corneum side in contact with the sample solution. The patch was applied on the SCE. The upper and lower parts of the Franz cell were sealed with Parafilm® and fastened together by means of a clamp, with the epidermis acting as a barrier between the donor and receptor compartments. These vertical cells had a wider column than the original Franz-type diffusion cell, and the bowl shape was removed [11] . They had a diffusion area of 0.636 cm 2 and a 5 mL (approx.) receptor compartment. The receiver volume of each cell was individually calibrated. The receiver compartments were filled with a freshly prepared degassed mixture of ethanol/water 50:50 v/v. Before use, the receptor solution was sonicated to remove dissolved air. Special care was taken that there were no air bubbles between the solution and the epidermis in the receptor compartment. The cells were kept at 37°C throughout the experiment, so that the skin surface temperature was 32±1°C. Only the receptor compartment was in contact with the circulating water at 37°C and each cell was equipped with a stirring magnet. At predetermined times (1, 3, 5, 7 and 24 h), 0.2 mL samples were withdrawn from the receiver compartment and immediately replaced with fresh receiver medium. Sink conditions were maintained throughout the experiment. The withdrawn samples were assayed directly by a CGC/FID method to determine the concentrations of the compounds that had permeated through the epidermis. All values are the average of three parallel experiments.
Permeation parameters: Permeation of T4OL across the epidermis can be described by Fick's 2nd law of diffusion [12] . Permeation parameters are interpreted from a cumulative drug amount per unit skin area Q/A versus time t plot. The gradient and x intercept of the linear portion of the plot yield steady-state flux and lag time accordingly.
Drug retention study:
The SCE samples were removed from the Franz diffusion cells over a 24 h period following application of the patch. Any residue on the surface of the skin was removed using a cotton tip applicator. Each SCE membrane was then briefly rinsed with 5 mL methanol and left to dry. The skin samples were then cut into small pieces, and placed in 10 mL of methanol. The suspension was sonicated for 30 min, soaked for 24 h at 4°C, and then filtered. The concentration of T4OL was assayed by the CGC/FID method reported below.
Terpinen-4-ol assay:
The samples were assayed by a CGC/FID method. Agilent Technologies model HP 6890 Series (Agilent Technologies Italia S.p.A., Italy) gas-chromatograph equipped with: autosampler HP 6890; split-splitless injector; the inlet stream splitter was operated with a splitter ratio of 30:1; FID detector; fused silica capillary column "HP-5" (5% phenyl methyl silicone; 15 m x 0.32 mm I.D., 0.25 μm film thickness).
Operating conditions: Constant inlet with an electronic control. Carrier gas. Helium: 1 mL/min; Detector gas. Hydrogen: 9 mL/min; Air: 350 mL/min. Operating temperature:
Injector. Constant temperature of 280°C; Detector. Constant temperature of 280°C; Column. Initial isotherm of 40°C for 10 min, from 40°C to 180°C at 2°C/min with an increment from 180°C to 280°C at 10°C/min. The concentration of terpene in the samples was calculated by using an internal standard. The limit of detection was 0.3μg/mL. Statistical analysis: t-Test for significant differences between means was performed using program SPSS 1 (Spss Inc., USA). Differences were considered significant at the p<0.05 level.
